Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC

Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC

Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with <sup>177</sup>Lu-labeled PSMA-ligands. Radionuclide therapy efficacy may even be improved by using the alpha emitter Ac-225. Higher efficacy is...

Full description

Bibliographic Details
Main Authors: Eline L. Hooijman, Yozlem Chalashkan, Sui Wai Ling, Figen F. Kahyargil, Marcel Segbers, Frank Bruchertseifer, Alfred Morgenstern, Yann Seimbille, Stijn L. W. Koolen, Tessa Brabander, Erik de Blois
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Pharmaceutics
Subjects:
actinium-225
[<sup>225</sup>Ac]Ac-PSMA-I&T
clinical translation
good manufacturing practice (GMP)
metastatic castration-resistant prostate cancer (mCRPC)
prostate-specific membrane antigen (PSMA) therapy and imaging (I&T)
Online Access:https://www.mdpi.com/1999-4923/13/5/715

Similar Items

Similar Items